Bernard Escudier
MD
Professor of Medical Oncology
👥Biography 个人简介
Bernard Escudier at Gustave Roussy is a pioneer in VEGFR-targeted therapy for RCC. He led the TARGET trial establishing sorafenib in second-line RCC and contributed to sunitinib development, shaping the first decade of molecular targeted therapy in advanced kidney cancer. His encyclopedic contributions to RCC clinical research span the entire evolution from cytokine therapy through targeted agents to immunotherapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Bernard Escudier 的研究动态
Follow Bernard Escudier's research updates
留下邮箱，当我们发布与 Bernard Escudier（Institut Gustave Roussy）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment